SEARCH

SEARCH BY CITATION

References

  • 1
    Valderrabano F, Jones EH, Mallick NP. Report on management of renal failure in Europe, XXIV, 1993. Nephrol Dial Transplant. 1995;10(suppl 5):125.
  • 2
    Collins AJ, Kasiske B, Herzog C, et al. Excerpts from the United States Renal Data System 2006 Annual Data Report. Am J Kidney Dis. 2007;1(suppl 1):A6A7, S1–S296.
  • 3
    Russo D, Napolitano P, Sirico ML, et al. A project to prevent renal diseases in the general population. J Nephrol. 2007;20:3642.
  • 4
    Coresh J, Astor BC, Greene T, et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis. 2003;41:112.
  • 5
    Xue JL, Ma JZ, Louis TA, et al. Forecast of the number of patients with end-stage renal disease in the United States to the year 2010. J Am Soc Nephrol. 2001;12: 27532758.
  • 6
    Wang Y, Wang QJ. The prevalence of prehypertension and hypertension among US adults according to the new joint national committee guidelines: new challenges of the old problem. Arch Intern Med. 2004;164:21262134.
  • 7
    Yamagata K, Ishida K, Sairenchi T, et al. Risk factors for chronic kidney disease in a community-based population: a 10-year follow-up study. Kidney Int. 2007;71:159166.
  • 8
    Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:19031913.
  • 9
    Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:12061252.
  • 10
    Moser M, Franklin SS. Hypertension management. Results of a new national survey for the Hypertension Education Foundation. Harris interactive. J Clin Hypertens (Greenwich). 2007;9:316323.
  • 11
    Ruggenenti P, Schieppati A, Remuzzi G. Progression, remission, regression of chronic renal diseases. Lancet. 2001;357:16011608.
  • 12
    Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851860.
  • 13
    Jacobsen P, Andersen S, Jensen BR, et al. Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy. J Am Soc Nephrol. 2003;14:992999.
  • 14
    Jacobsen P, Andersen S, Rossing K, et al. Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy. Kidney Int. 2003;63:18741880.
  • 15
    Nakao N, Yoshimura A, Morita H, et al. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet. 2003;361:117124.
  • 16
    Bianchi S, Bigazzi R, Caiazza A, et al. A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis. 2003;41:565570.
  • 17
    Sandhu S, Wiebe N, Fried LF, et al. Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol. 2006;17:20062016.
  • 18
    Mancia G, Parati G, Borghi C, et al. Hypertension prevalence, awareness, control and association with metabolic abnormalities in the San Marino population: the SMOOTH study. J Hypertens. 2006;24:837843.
  • 19
    Macedo ME, Lima MJ, Silva AO, et al. Prevalence, awareness, treatment and control of hypertension in Portugal: the PAP study. J Hypertens. 2005;23:16611666.
  • 20
    Colhoun HM, Dong W, Poulter NR. Blood pressure screening, management and control in England: results from the health survey for England 1994. J Hypertens. 1998;16:747752.
  • 21
    Banegas JR, Guallar-Castillon P, Rodriguez-Artalejo F, et al. Association between awareness, treatment, and control of hypertension, and quality of life among older adults in Spain. Am J Hypertens. 2006;19:686693.
  • 22
    Wolf-Maier K, Cooper RS, Banegas JR, et al. Hypertension prevalence and blood pressure levels in six European countries, Canada, and the United States. JAMA. 2003;289:23632369.
  • 23
    Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA. 2003;289:25602572.
  • 24
    Viera AJ, Kshirsagar AV, Hinderliter AL. Lifestyle modifications to lower or control high blood pressure: is advice associated with action? The behavioral risk factor surveillance survey. J Clin Hypertens (Greenwich). 2008;10: 105111.
  • 25
    Ohmit SE, Flack JM, Peters RM, et al. Longitudinal Study of the National Kidney Foundation’s (NKF) Kidney Early Evaluation Program (KEEP). J Am Soc Nephrol. 2003;7(suppl 2):S117S121.
  • 26
    Arnlov J, Evans JC, Meigs JB, et al. Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study. Circulation. 2005;112:969975.
  • 27
    Verhave JC, Gansevoort RT, Hillege HL, et al. An elevated urinary albumin excretion predicts de novo development of renal function impairment in the general population. Kidney Int Suppl. 2004;66: S18S21.
  • 28
    Iseki K, Ikemiya Y, Iseki C, et al. Proteinuria and the risk of developing end-stage renal disease. Kidney Int. 2003;63:14681474.
  • 29
    Keane WF, Brenner BM, De Zeeuw D, et al. The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study. Kidney Int. 2003;63:14991507.
  • 30
    Wachtell K, Ibsen H, Olsen MH, et al. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann Intern Med. 2003;139:901906.
  • 31
    Gerstein HC, Mann JF, Yi Q, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA. 2001;286:421426.
  • 32
    Parving HH, Lewis JB, Ravid M, et al. Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective. Kidney Int. 2006;69:20572063.
  • 33
    Wachtell K, Palmieri V, Olsen MH, et al. Urine albumin/creatinine ratio and echocardiographic left ventricular structure and function in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. Losartan intervention for endpoint reduction. Am Heart J. 2002;143:319326.
  • 34
    De Zeeuw D, Parving HH, Henning RH. Microalbuminuria as an early marker for cardiovascular disease. J Am Soc Nephrol. 2006;17:21002105.
  • 35
    Brantsma AH, Bakker SJ, De Zeeuw D, et al. Urinary albumin excretion as a predictor of the development of hypertension in the general population. J Am Soc Nephrol. 2006;17:331335.
  • 36
    Brantsma AH, Bakker SJ, Hillege HL, et al. Urinary albumin excretion and its relation with C-reactive protein and the metabolic syndrome in the prediction of type 2 diabetes. Diabetes Care. 2005;28:25252530.
  • 37
    De Jong PE, Van Der Velde M, Gansevoort RT, et al. Screening for chronic kidney disease: where does Europe go? Clin J Am Soc Nephrol. 2008;3:616623.